An Information Tool Incorporating Real-World Outcome Data for Women With Metastatic Breast Cancer Eligible for Treatment With a CDK4/6 Inhibitor: Development and Evaluation
Most patients valued the inclusion of real-world outcome data in the information tool, although many found it challenging to process, and some described the outcome data as overwhelming, underscoring the importance of careful framing and delivery.
Abstract
Abstract Background Accelerating the transition to value-based health care (VBHC) is essential to ensure sustainable care delivery. VBHC maximizes patient value by optimizing outcomes, controlling costs, and leveraging data to improve quality and patient-doctor communication. Integrating real-world data in health care is important to achieve informed decisions, especially in palliative care, where choices are complex. Objective This study described the development and pilot-testing of an information tool that incorporates real-world outcome data for women with metastatic breast cancer who are initiating CDK4/6 inhibitor treatment. Real-world insights are needed to better inform these patients, in particular because real-world outcomes are known to differ from trial results because of larger heterogeneity in patient characteristics, and differences in frequency of check-ups and handling side effects. Methods We developed an information tool together with patient representatives and clinicians using a participatory development approach that consisted of five key steps: (1) establishment of a multidisciplinary steering group (n=10 steering group members), (2) mapping of the patient journey and patients’ needs through focus groups (n=9) and semistructured interviews (n=8), (3) extraction of real-world outcome data from electronic health records systems of 229 patients, (4) prototyping of the tool (n=10), and (5) pilot evaluation with the targeted patient population using semistructured interviews (n=38). We used qualitative analysis methods to analyze the focus group and interview data. Results We developed a tool consisting of (1) a communication aid for use during doctor-patient consultations (ie, KIJKgesprek [Stichting Kijksluiter]) and (2) a 2-component companion app with informational videos for use at home, both incorporating real-world outcome data (ie, KIJKbericht and KIJKsluiter [Stichting Kijksluiter]). Participants valued the tool for its clarity and structured design, reporting that the outcome data reinforced their experiences and facilitated the setting of realistic expectations. However, some participants described the outcome data as overwhelming, underscoring the importance of careful framing and delivery. Preferences regarding the type, level of detail, and timing of information presentation varied among participants, highlighting the necessity of individualizing information tools to meet diverse informational needs. Conclusions Most patients valued the inclusion of real-world outcome data in the information tool, although many found it challenging to process. Preferences for the type and presentation of information varied widely among individuals. Information tools incorporating outcome data have the potential to enhance patient understanding and support informed decision-making about care that they value most. However, these tools must be designed to allow for customization, ensuring they address individual informational needs and preferences effectively.
Introduction Existing research has linked increased patient participation in oncology care to greater patient satisfaction, enhanced quality of life, and improved healthcare utilization among patients with cancer. Yet, current measures of patient engagement and similar constructs do not reflect the unique experiences o...
Carolyn Hagler, S. Kircher, G. Wismer et al.· Frontiers in Oncology· 0 citations
Background Metastatic breast cancer (MBC) remains a treatable, but incurable disease. Anti-cancer treatments and supportive therapies aim to control disease, prolong survival, ameliorate physical symptoms and improve quality of life (QoL). Currently, no validated MBC-specific patient-reported outcome measures exist, an...
C. Bedding, K. Absolom, K. Pogoda et al.· Breast· 0 citations
EPROs represent a shift from episodic, visit-based assessment to more continuous and responsive monitoring in breast cancer care, and their clinical value is strongest when integrated into care pathways with clearly defined responsibilities and actionable workflows.
Thanate Dajsakdipon, Luca Formenti, E. Ferraro et al.· Current Opinion in Oncology· 0 citations
Introduction The Global Lung Cancer Coalition Patient Charter highlights that every patient should have involvement in decision-making. In lung cancer, patient involvement in treatment decision-making is often perceived as difficult to achieve. Purpose This study explored the experiences of patients with epidermal grow...
V. Harrison, Gerald Goh· Patient Preference and Adher...· 0 citations
Purpose Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer (EBC) is treated with curative intent, but risk of recurrence (RoR) remains a challenge. The identification of high RoR EBC patients is inconsistent, highlighting the need for a simplified approach. This...
K. Mallavarapu, Rakesh Reddy B, Somashekhar Sp et al.· Breast Cancer· 0 citations
BACKGROUND
Improving patient-centered care and communication in breast cancer remains challenging in the complex and evolving landscape of breast cancer care delivery.
METHODS
The SharES (Alliance A231901CD) trial was carried out in collaboration with the NCI Community Oncology Research Program Alliance Research Base...
Sarah T. Hawley, K. Kidwell, R. Jagsi et al.· JNCI Cancer Spectrum· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.